Keyphrases
2-cycles
14%
Advanced Gastric Cancer
80%
Amrubicin
14%
Antiangiogenic Agents
14%
Capecitabine Plus Oxaliplatin
14%
Carbohydrate Antigen 125 (CA125)
14%
Chemotherapy
25%
Cisplatin
14%
Clinical Trial Participation
14%
Clinical Trials
14%
Combination Chemotherapy
28%
Conventional Chemotherapy
14%
Cytotoxic Agents
14%
Gastric Cancer
31%
Gastric Neuroendocrine Carcinoma
28%
Gastrointestinal Stromal Tumor
28%
Highly Effective
14%
Imatinib
28%
Immune Checkpoint Inhibitor Monotherapy
14%
Immune Checkpoint Inhibitors
17%
Immune-related Adverse Events
28%
Irinotecan
14%
Liver Metastasis
14%
MFOLFOX6
14%
Monotherapy
14%
Multiple Liver Metastases
14%
Neuroendocrine Carcinoma
28%
Nivolumab
42%
Older Men
17%
Overall Survival
16%
Paclitaxel
28%
Pembrolizumab
28%
Peritoneal Metastasis
14%
Potential Biomarkers
14%
Progression Pattern
14%
Pulmonary Neuroendocrine Carcinoma
14%
Ramucirumab
42%
Rare Diseases
14%
Rectum
28%
Regorafenib
28%
Retrospective Analysis
28%
Second-line Chemotherapy
14%
Severe Jaundice
14%
Severe Peritoneal Metastasis
14%
Stomach
28%
Sunitinib
28%
Taxanes
14%
Third-line Treatment
19%
Tumor Endothelial Cells
14%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Adverse Event
37%
Amrubicin
5%
Antiangiogenic
5%
Ascites
7%
Bilirubin
7%
Biological Marker
14%
Capecitabine Plus Oxaliplatin
14%
Carbohydrate Antigen
14%
Chemotherapy
50%
Cisplatin
9%
Clinical Trial
14%
Cytotoxic Agent
5%
Diarrhea
7%
Gastrointestinal Stromal Tumor
28%
Imatinib
28%
Immune Checkpoint Inhibitor
17%
Irinotecan
5%
Jaundice
14%
Liver Metastasis
28%
Monotherapy
19%
Neoplasm
5%
Neuroendocrine Carcinoma
28%
Nivolumab
42%
Overall Survival
21%
Paclitaxel
28%
Pelvic Pain
5%
Pembrolizumab
28%
Peritoneum Metastasis
28%
Progression Free Survival
13%
Ramucirumab
42%
Rare Disease
5%
Regorafenib
28%
Second-Line Chemotherapy
5%
Sunitinib
28%
Taxane
14%
Vasculotropin C
5%
Medicine and Dentistry
Abdominal Cancer
71%
Adverse Event
7%
Ascites
7%
Biological Marker
14%
Carbohydrate Antigen
14%
Chemotherapy
8%
Cholangitis
8%
Common Bile Duct Stone
14%
Endoscopic Therapy
5%
Immune Checkpoint Inhibitor
17%
Immune-Related Adverse Events
30%
Liver Metastasis
14%
Monotherapy
14%
Nivolumab
42%
Overall Survival
17%
Pembrolizumab
28%
Peritoneum Metastasis
28%
Progression Free Survival
13%
Ramucirumab
14%
Stenting
14%